Michelle Dolan
,
Credentials
MD
Bio
Dr. Dolan is a clinical cytogeneticist, associate director of the Cytogenetics Laboratory, and a member of the Division of Molecular Pathology and Genomics. She currently collaborates in research projects with colleagues in areas as diverse as surgical pathology, hematopathology, oncology and bone marrow transplantation, and oral pathology. She has ongoing collaborations with Dr. Celalettin Ustun in the Division of Hematology, Oncology and Transplantation exploring the impact of cytogenetic findings on hematopoietic stem cell transplant outcomes. These projects have investigated the role of classical (G-banding) and molecular cytogenetics (fluorescence in situ hybridization, FISH) in assessing the level of disease burden before bone marrow or stem cell transplantation.In another collaboration with Drs. Ustun, Michael Linden (Laboratory Medicine and Pathology) and others in the United States and internationally, Dolan is exploring the role of mast cells in core-binding factor acute myeloid leukemias. Dolan is also working with Dr. Ustun and Drs. Linden, Sophia Yohe and Elizabeth Courville (Laboratory Medicine and Pathology) on a project to determine if residual disease at the time of transplant, as assessed by cytogenetic and other methods, impacts outcomes of various types of pre-transplant conditioning regimens.Dolan is also collaborating with Dr. Aleksandr Lazaryan and colleagues in the Division of Hematology, Oncology and Transplantation in a study to determine the prognostic significance of cytogenetic abnormalities in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission.Dolan is a co-investigator with Dr. Ioannis Koutlas and others in the Department of Oral Pathology in studies designed to determine whether the PLAG1 gene is rearranged in entities other than pleomorphic adenomas arising in salivary glands. She is also working with a colleague at Vanderbilt University on an immunohistochemical and FISH study of Ewing sarcoma and atypical teratoid/rhabdoid tumors.
Publications
- Naumchik B, Weigel BJ, Murati MA, Rudzinski E, Paulson V, Lockwood CM, Dolan M, Flanagan S, Luquette M. Congenital infantile fibrosarcoma involving pelvic wall and thigh soft tissues and placenta, presenting with coagulopathy. Pediatr Dev Pathol. 2022 Jul 14:10935266221114017. doi: 10.1177/10935266221114017.
- Han SY, Mrózek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Møller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 May 25;5(10):2481-2489. doi: 10.1182/bloodadvances.2020003605.
- Erickson BE, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, and Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology, 2020; 159 (1): 17-22. https://doi.org/10.1016/j.ygyno.2020.07.016.
- Ustun, C., Morgan, E.A., Ritz, E.M., Vestergaard, H., Pullarkat, S., Kluin, P.M., Ohgami, R., Baughn, L.B., Kim, Y., Ku, N.K., Czuchlewski, D., Boe Møller, M., Schiefer, A.‐I., Mrózek, K., Horny, H.‐P., George, T.I., Kielsgaard Kristensen, T., Beck, T., Nathan, S., Arana Yi, C., Yeung, C., Pullarkat, V., Gotlib, J., Akin, C., Kohlschmidt, J., Salhotra, A., Soma, L., Chen, D., Han, S.Y., Cho, C., Sperr, W., Broesby‐Olsen, S., Linden, M.A., Dolan, M., Hoermann, G., Hornick, J.L., Bloomfield, C., Nakamura, R., Joachim Deeg, H., Litzow, M.R., Borthakur, G., Weisdorf, D., Huls, G., Perales, M.‐A., Valent, P. and Marcucci, G. Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol., 2020. doi:10.1111/ijlh.13338.
- Gilles SR, Yohe SL, Linden MA, Dolan M, Hirsch B, Grzywacz B. CD161 Is expressed in a subset of T-cell prolymphocytic leukemia cases and Is useful for disease follow-up.Am J Clin Pathol. 2019 Sep 9;152(4):471-478. doi: 10.1093/ajcp/aqz060.
Contact
Address
15-180 Phillips-Wangensteen Bldg516 Delaware St SE
Minneapolis, MN 55455